ImmuPharma plc

LSE:IMM.L

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United Kingdom

Market Cap

USD 13.04 M

Share Price

USD 0.03

Avg Daily Volume

3,007,520

Change (1 day)

-2.82%

Change (1 year)

11.80%

Change (YTD)

107.20%

ImmuPharma plc Revenue for the year ending December 31, 2024

ImmuPharma plc Revenue is NA for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

ImmuPharma plc Revenue for the year ending December 31, 2023 was USD 0.00.
ImmuPharma plc Revenue for the year ending December 31, 2022 was USD 0.00, a -100.00% change year over year.
ImmuPharma plc Revenue for the year ending December 31, 2021 was USD 160.15 K, a -7.41% change year over year.
ImmuPharma plc Revenue for the year ending December 31, 2020 was USD 172.98 K, a 67.53% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

LSE: IMM.L

ImmuPharma plc

CEO	Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA
IPO Date	Oct. 28, 2003
Location	United Kingdom
Headquarters	1 Bartholomew Close
Employees	5
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.